Transgenic model evaluation II (Aspartame): Target Organs and Levels of Evidence for GMM-01
Toxicology Studies of Aspartame (CASRN 22839-47-0) in Genetically Modified (FVB Tg.AC Hemizygous) and B6.129-Cdkm2atn1Rdp (N2) Deficient Mice and Carcinogenicity Studies of Aspartame in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Feed Studies)
Chemical (Study Title)
CASRN
|
Peer Review Date
|
Primary Uses
|
Route/Exposure Levels
|
Study Laboratory
|
Transgenic model evaluation II (Aspartame)
22839-47-0
|
05/22/2003
|
Artificial sweetener to be tested using various strains of transgenic animal models.
|
Dosed-Feed
0, 3,125, 6,250, 12,500, 25,000 or 50,000 ppm; 15 animals/sex/dose
|
BioReliance, Inc
|
Levels of evidence information for Feed and Genetic Toxicology Studies of Aspartame in Tg.AC Hemizygous Mice
|
|
Male Tg.AC Hemizygous Mice
|
Female Tg.AC Hemizygous Mice
|
|
|
39 Weeks
|
39 Weeks
|
|
Neoplastic Lesions
|
None
|
None
|
|
Non-Neoplastic Lesions
|
None
|
None
|
Levels of evidence information for Feed and Genetic Toxicology Studies of Aspartame in p53 Haploinsufficient Mice
|
|
Male p53 Haploinsufficient Mice
|
Female p53 Haploinsufficient Mice
|
|
|
39 Weeks
|
39 Weeks
|
|
Levels of Evidence
|
No Evidence
|
No Evidence
|
|
Neoplastic Lesions
|
None
|
None
|
|
Non-Neoplastic Lesions
|
None
|
None
|
Levels of evidence information for Feed and Genetic Toxicology Studies of Aspartame in Cdkn2a Deficient Mice
|
|
Male Cdkn2a Deficient Mice
|
Female Cdkn2a Deficient Mice
|
|
|
39 Weeks
|
39 Weeks
|
|
Levels of Evidence
|
No Evidence
|
No Evidence
|
|
Neoplastic Lesions
|
None
|
None
|
|
Non-Neoplastic Lesions
|
Liver: hepatocyte, cytoplasmic periportal vacuolization
|
None
|
